COGT

COGT

USD

Cogent Biosciences Inc. Common Stock

$14.130-1.110 (-7.283%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$15.240

最高价

$15.870

最低价

$13.980

成交量

0.44M

公司基本面

市值

2.0B

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

1.89M

交易所

NMS

货币

USD

52周价格范围

最低价 $3.72当前价 $14.130最高价 $17.15

相关新闻

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences with a Buy and maintains $21 price target.

查看更多
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target
GlobeNewswire

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA)

查看更多
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
GlobeNewswire

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent's newest preclinical program;

查看更多
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
GlobeNewswire

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today

查看更多
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Analyst Upgrades

JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $44

JP Morgan analyst Anupam Rama maintains Cogent Biosciences with a Overweight and raises the price target from $30 to $44.

查看更多
JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $44